AR121669A1 - Compuesto de piridazina sustituida - Google Patents

Compuesto de piridazina sustituida

Info

Publication number
AR121669A1
AR121669A1 ARP210100758A ARP210100758A AR121669A1 AR 121669 A1 AR121669 A1 AR 121669A1 AR P210100758 A ARP210100758 A AR P210100758A AR P210100758 A ARP210100758 A AR P210100758A AR 121669 A1 AR121669 A1 AR 121669A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogenated
cycloalkyl
formula
alkylene
Prior art date
Application number
ARP210100758A
Other languages
English (en)
Inventor
Yusuke Inagaki
Takashi Kamikubo
Takahiro Nigawara
Junko Maeda
Susumu Yamaki
Ikumi Kuriwaki
Maiko Iida
Junichi Shishikura
Yuka Koizumi
Kenji Negoro
Takanori Koike
Kengo Saba
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR121669A1 publication Critical patent/AR121669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de piridazina sustituida como inhibidores de la activación de inflamasoma NLRP3, una composición farmacéutica que comprende a uno de éstos compuestos y el uso de los mismos para el tratamiento de una enfermedad inflamatoria o neurodegenerativa. Reivindicación 1: Un compuesto de la fórmula (1) o una sal de este, caracterizado por que Ar es un grupo representado por la siguiente fórmula (2) ó (3), donde * representa un sitio de enlace al anillo piridazina de la fórmula (1); L es alquileno C₁₋₆ o cicloalquileno C₃₋₈; R¹ es H, alquilo C₁₋₆, cicloalquilo C₃₋₈, arilo, heteroarilo opcionalmente sustituido con 1 a 4 alquilos C₁₋₆, ciano, -OR⁷ o -N(alquilo C₁₋₆)₂; R² es H, alquilo C₁₋₆, cicloalquilo C₃₋₈, arilo, heteroarilo opcionalmente sustituido con 1 a 4 alquilos C₁₋₆, ciano, -OR⁷, -N(alquilo C₁₋₆)₂, -C(=O)O-alquilo C₁₋₆ o -C(=O)NR⁸R⁹; R³ es OH, -NHC(=O)R¹⁰ o -OC(=O)-alquilo C₁₋₆; R⁴ es halógeno, O-alquilo C₁₋₆ o alquilo C₁₋₆ halogenado; R⁵ es H, cicloalquilo C₃₋₈ o alquilo C₁₋₆ halogenado; R⁶ es H, halógeno, -O-alquilo C₁₋₆ o alquilo C₁₋₆ halogenado; R⁷ es -alquileno C₁₋₆-O-alquileno C₁₋₆-arilo o alquilo C₁₋₆ halogenado; R⁸ y R⁹ son iguales o diferentes, y cada uno es H o alquilo C₁₋₆; o R⁸ y R⁹, juntos con un átomo de nitrógeno al cual R⁸ y R⁹ están enlazados, forman morfolina, piperazina o tiomorfolina y la morfolina, piperazina o tiomorfolina está opcionalmente sustituida con alquilo C₁₋₆; y R¹⁰ es alquilo C₁₋₆, alquilo C₁₋₆ halogenado o cicloalquilo C₃₋₈, siempre que, cuando Ar es un grupo representado por la fórmula (2) con R⁵ que es H, R⁴ es alquilo C₁₋₆ halogenado, y uno de R¹ y R² es un grupo diferente que H.
ARP210100758A 2020-03-27 2021-03-26 Compuesto de piridazina sustituida AR121669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020057623 2020-03-27

Publications (1)

Publication Number Publication Date
AR121669A1 true AR121669A1 (es) 2022-06-29

Family

ID=77890352

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100758A AR121669A1 (es) 2020-03-27 2021-03-26 Compuesto de piridazina sustituida

Country Status (7)

Country Link
US (1) US20230107277A1 (es)
EP (1) EP4129986A4 (es)
JP (1) JPWO2021193897A1 (es)
CN (1) CN115279739A (es)
AR (1) AR121669A1 (es)
TW (1) TW202204323A (es)
WO (1) WO2021193897A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN116867769A (zh) * 2021-02-08 2023-10-10 南京明德新药研发有限公司 取代的哒嗪苯酚类衍生物
CA3218212A1 (en) 2021-04-28 2022-11-03 Astellas Pharma Inc. Substituted triazine compound
AU2022304254A1 (en) 2021-07-02 2024-02-08 Astrazeneca Ab Nlrp3 inflammasome inhibitors
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
WO2023088987A1 (en) * 2021-11-19 2023-05-25 F. Hoffmann-La Roche Ag Pyridazine derivatives as inhibitors of nlrp3
WO2023186020A1 (en) * 2022-03-31 2023-10-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
WO2023220408A1 (en) * 2022-05-13 2023-11-16 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
WO2024006559A1 (en) * 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
WO2024012551A1 (zh) * 2022-07-14 2024-01-18 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
US20240124451A1 (en) 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2024090469A1 (ja) * 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
CN117986258A (zh) * 2022-11-04 2024-05-07 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2024160690A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv 2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors
WO2024160692A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
WO2024160694A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
WO2024160691A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv PYRROLO[1,2-d][1,2,4]TRIAZINES AND PYRAZOLO[1,5-d] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS
WO2024160693A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
WO2024169858A1 (zh) * 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473522A1 (fr) * 1980-01-16 1981-07-17 Synthelabo Nouveaux derives substitues de dihydro-2,3 imidazo(1,2-b)pyridazines et les medicaments, utiles notamment comme antidepresseurs, qui en contiennent
FR2663326B2 (fr) * 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2017184604A1 (en) 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
ES2906280T3 (es) * 2017-07-07 2022-04-18 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
US20230107277A1 (en) 2023-04-06
EP4129986A4 (en) 2024-05-22
EP4129986A1 (en) 2023-02-08
TW202204323A (zh) 2022-02-01
WO2021193897A1 (ja) 2021-09-30
JPWO2021193897A1 (es) 2021-09-30
CN115279739A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
AR121669A1 (es) Compuesto de piridazina sustituida
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR093364A1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR091185A1 (es) Derivados de 1,2,4-triazol
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR108610A1 (es) Derivados de imidazolona inhibidores de la elastasa de neutrófilos humana
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas
AR123884A1 (es) Compuestos moduladores del cftr, composiciones y usos de estos
AR100126A1 (es) Activadores de herg policíclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure